Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
24.2 USD | -1.35% | -3.05% | -22.01% |
05-20 | Insmed Lung Infections Treatment Study Shows Improvement | MT |
05-15 | Goldman Sachs Adjusts Price Target on Insmed to $49 From $40, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.01% | 3.65B | |
+10.15% | 114B | |
+12.72% | 107B | |
-5.50% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.39% | 17.51B | |
-39.36% | 17.17B | |
+6.60% | 14.14B | |
+34.81% | 12.2B |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Cowen Adjusts Insmed's Price Target to $53 From $56, Maintains Outperform Rating